Vilanterol
 | |
| Systematic (IUPAC) name | |
|---|---|
|
4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | 503068-34-6 |
| ATC code |
R03AK10 (WHO) (+fluticasone) R03AL03 (WHO) (+umeclidinium) |
| PubChem | CID 10184665 |
| ChemSpider | 8360167 |
| ChEBI | CHEBI:75037 |
| Chemical data | |
| Formula | C24H33Cl2NO5 |
| Molar mass | 486.43 g/mol |
| |
| |
Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1]
Vilanterol is available in following combinations:
- with inhaled corticosteroid fluticasone furoate — fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S.), Relvar Ellipta (EU, RU))
- with muscarinic antagonist umeclidinium bromide — umeclidinium bromide/vilanterol (trade name Anoro Ellipta)
See also
- Salmeterol — a long-acting β2 adrenoreceptor agonist (LABA) with a similar backbone.
References
- ↑ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Retrieved 10 May 2013.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.